Press releases & news


2cureX continues to update its frequently asked Question page on




2cureX AB (“2cureX”) announced today that as part of its constructive and active dialogue with its stakeholders the 2cureX Q&A section on the website has been updated:




Certified Adviser

Sedermera Fondkommission is the Certified Adviser of 2cureX.


For more information about 2cureX:

Ole Thastrup, CEO;


Phone: +45 22 11 53 99;



About 2cureX

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.


IndiTreat® is currently being clinically validated in colorectal and ovarian cancer.


The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).


Contact information

Laboratory: 2cureX, Fruebjergvej 3, 2100 Copenhagen Ø, Denmark| Phone: +45 2211 5399| E-mail:

Privacy Policy | Imprint